Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) has provided an announcement.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced a new arrangement to disseminate corporate communications to its H Shareholders electronically, in compliance with the Listing Rules of the Hong Kong Stock Exchange. This move is aimed at enhancing the efficiency of communication with shareholders, although printed copies will still be available upon request. The initiative reflects the company’s commitment to modernizing its operations and improving shareholder engagement, potentially impacting its industry positioning by setting a precedent for digital communication practices.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$80.57 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, focusing on the pharmaceutical industry. It is listed on the Stock Exchange of Hong Kong Limited and is known for its development and distribution of pharmaceutical products.
Average Trading Volume: 4,737,589
Current Market Cap: HK$478.9B
See more insights into 1276 stock on TipRanks’ Stock Analysis page.